As a leader in heart valves for over 60 years, Edwards Lifesciences is dedicated to providing you a destination for the latest transcatheter heart valve information, tools, resources, and innovative solutions.

New PARTNER 3 trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year
  • Time: The only transcatheter heart valve with 90% survival at 5 years
  • Management: The only transcatheter heart valve with a THV-in-THV indication*

*For patients assessed at high-risk for surgical replacement.

Build for now and what's next

Edwards SAPIEN platform: The move for lifetime management

Your strategy for lifetime management starts with the Edwards SAPIEN 3 platform. When the first valve choice matters, the SAPIEN 3 platform is designed to deliver a reliable TAVI experience so patients can live their best lives.1,2,3

Explore Edwards SAPIEN 3 platform for lifetime management

Learning and advancement

Interventional cadiologist taking notes

Strengthening your care for patients

Industry experts share the latest interventional techniques and provide their advice on how best to adopt them within clinical practice.

About our programs

Edwards Benchmark Program

Our program may support your heart centre in optimising its transcatheter aortic valve implantation (TAVI) care pathway for better patient outcomes.

Learn more

Tips and Techniques

Explore case recordings, expert-delivered educational videos on procedural challenges, tips and techniques, peer interviews and more.

View videos

Learning Portal

Edwards Learning Network, an educational portal for healthcare professionals providing continuous learning and development in structural heart intervention.

Find out more

Edwards SAPIEN 3 platform

Close up of Edwards SAPIEN 3 Ultra transcatheter heart valve
Edwards SAPIEN 3 Ultra valve

The latest transcathether heart valve in the Edwards portfolio.

Edwards SAPIEN 3 Ultra valve
Close up of Edwards SAPIEN 3 transcatheter heart valve
Edwards SAPIEN 3 valve

The first TAVI valve to receive a CE mark for severe aortic stenosis (sAS) patients at low surgical risk.

Edwards SAPIEN 3 valve
Close up of Edwards SAPIEN XT transcather heart valve
Edwards SAPIEN XT valve

Edwards valve proving non-inferior to surgery on mortality and stroke in the PARTNER IIA Trial.4

Technology and Innovation
Close up of Edwards SAPIEN XT transcather heart valve
Edwards SAPIEN valve

Introduced as a lifesaving treatment option for inoperable and high surgical risk patients.5,6

Explore Edwards Innovation

Clinical Evidence

Male doctor researching on laptop


Overview of studies conducted with balloon expandable TAVI valves by Edwards Lifesciences.

Read PARTNER data

ESC/EACTS VHD Guidelines

Learn how the Edwards clinical trial programme has shaped the aortic stenosis treatment landscape.

TAVI value and optimisation

Uncover the wide-ranging economic and quality of life benefits possible with the Edwards SAPIEN 3 transcatheter heart valve.7

Speaker speaking at a conference


Visit us at upcoming events

Upcoming events and past event highlights.

Read more
Female interventional cardiologist holding a microphone presenting to a room full of doctors


Resources for download

Useful for you and your patients, including heart anatomy guide, clinical summary PDFs and more.

Access resources

Stay informed with our newsletter


1. Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1695-1705.
2. Tarantini G, et al. Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve. Circ Cardiovasc Interv. 2020 Jul;13(7):e008972.
3. Pibarot P, et al. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. J Am Coll Cardiol. 2020 Oct 20;76(16):1830-1843.
4. Leon MB, et al. N Engl J Med 2016;374:1609-1620 and supplementary material.
5. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
6. Smith CR, Leon MB, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
7. Galper BZ, et al. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation. 2023 May 23;147(21):1594-1605.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, Edwards Benchmark, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, PARTNER, PARTNER II, and PARTNER 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property if their respective owners.

PP--EU-6940 v1.0